FGFR2 and infantile convulsions and choreoathetosis: Several phase III trials are ongoing in first-line settings for metastatic iCCA; in particular, the PROOF Trial evaluates the efficacy and safety of infigratinib versus gemcitabine and cisplatin (with a 2:1 randomization) in patients with FGFR2 gene fusions/translocations [56].